First patient dosed in trial of dual-transgene intravitreal gene therapy for wet AMD
The first patient has been dosed in a phase 1/2 clinical trial investigating 4D-150 for the treatment of wet age-related macular degeneration, according to a press release from 4D Molecular Therapeutics.“4D-150 is a dual-transgene intravitreal gene therapy incorporating the R100 capsid, which we invented through our proprietary Therapeutic Vector Evolution platform,” David Kirn, MD,
Source: healio.com
